Our Network of Board-Certified Providers
Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
Across Connecticut — from Ansonia to smaller cities and towns — patients who previously avoided GLP-1 treatment due to needle phobia are now accessing oral semaglutide through licensed telehealth. Our CT-licensed physician network evaluates eligibility and prescribes Rybelsus (oral semaglutide) or other oral GLP-1 options entirely online, without a single injection.
Oral semaglutide (Rybelsus) is the FDA-approved pill form of the same active compound found in Ozempic and Wegovy. PIONEER clinical trials confirmed 3-8% body weight reduction with oral semaglutide — a meaningful result delivered without injections. For needle-averse Connecticut patients, this changes everything.[1][2]
Medically reviewed by
Dr. Sarah Mitchell, MD, ABOM
Board-Certified in Obesity Medicine • Last reviewed: June 6, 2026
Connecticut supports telehealth prescribing, allowing CT-licensed physicians to serve patients in every part of the state — from major metros to rural areas. Oral semaglutide is prescribed online, then shipped directly to your CT home from a licensed US pharmacy. No clinic visits, no injection training, no needles.
Find your city below and connect with a Connecticut-licensed physician who can prescribe oral semaglutide or other needle-free GLP-1 options.
Three randomized controlled trials published in the New England Journal of Medicine establish the evidence base for FDA-approved GLP-1 medications:
Connecticut authorizes board-certified licensed physicians to prescribe FDA-approved GLP-1 medications via telehealth after a valid patient-physician relationship is established through an online consultation. GLP-1 receptor agonists are not DEA-scheduled controlled substances — no in-person visit is legally required in Connecticut.
Our needle-free GLP-1 telehealth network extends beyond Connecticut and into neighboring states — oral semaglutide prescriptions wherever you are.
Oral semaglutide and needle-free GLP-1 options are available to patients in major cities across the United States through our licensed telehealth network.
Local weight loss and GLP-1 providers serving the Connecticut area, based on Google Business listings.
665 N Colony Rd, Wallingford, CT 06492
(203) 269-8000
4.8/5 ★ (53 reviews)
Visit website →Glastonbury, CT
(860) 430-6317
4.9/5 ★ (18 reviews)
Visit website →Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
Yes, in every city across Connecticut. Our network of CT-licensed telehealth physicians prescribes oral semaglutide (Rybelsus) and other needle-free GLP-1 options to eligible residents. The entire process — from consultation to delivery — involves zero injections.
Connecticut patients can access FDA-approved oral semaglutide (Rybelsus) in 3mg, 7mg, and 14mg doses through our telehealth platform. Injectable options like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are also available for patients who prefer them or who are better suited to injections.
Once prescribed, your oral semaglutide tablets ship from a licensed US pharmacy to any Connecticut address. Delivery typically takes 3-5 business days. Unlike injectable GLP-1, oral tablets do not require cold-chain shipping, making delivery straightforward to any location in Connecticut.
All physicians in our network hold active CT medical licenses and are fully authorized to prescribe FDA-approved medications including oral semaglutide (Rybelsus) to eligible residents. All prescriptions comply with Connecticut telehealth and prescribing regulations.
PIONEER clinical trial data shows oral semaglutide produces an average of 3-8%% body weight reduction over the treatment period. While somewhat less than injectable GLP-1 (10-15%%), oral semaglutide provides meaningful, clinically significant weight loss for patients who would not otherwise use injectable GLP-1. Results vary by individual and adherence to the strict dosing protocol.
Black Box Warning: In rodent studies, semaglutide and tirzepatide caused thyroid C-cell tumors. It is unknown whether GLP-1 receptor agonists cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. These medications are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Common side effects may include nausea, vomiting, diarrhea, constipation, abdominal pain, headache, and injection site reactions. These typically diminish as dosage is gradually escalated.
Serious side effects may include pancreatitis, gallbladder problems, kidney injury, hypoglycemia (with insulin), and allergic reactions. Consult your healthcare provider immediately if you experience severe symptoms.
Contraindications: History of medullary thyroid carcinoma, MEN 2, pancreatitis, pregnancy or breastfeeding, severe gastrointestinal disease. This is not a complete list — always discuss your full medical history with your physician.
Clinical References:
